Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GBR 830 in moderate-to-severe atopic dermatitis
NCT02683928Phase 2Completed
- Sponsor
- Ichnos Sciences Inc.
- Start
- Mar 2016
- Primary completion
- Jun 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing GBR 830 with Placebo (2 arms). Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 16 weeks, Change From Baseline in Thickness of Lesional Skin Biopsies at Day 71 and 1 more. Started Mar 2016; status: completed.
02
Drugs
telazorlimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02683928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02683928.